HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Overview
USA - NASDAQ:HRMY - US4131971040 - Common Stock
HRMY Key Statistics, Chart & Performance
The current stock price of HRMY is 32.24 USD. In the past month the price decreased by -10.92%. In the past year, price decreased by -16.95%.
HRMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.15 | 720.66B | ||
| JNJ | JOHNSON & JOHNSON | 17.51 | 421.80B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.63 | 274.38B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.92 | 238.46B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.29 | 237.99B | ||
| MRK | MERCK & CO. INC. | 10.61 | 204.02B | ||
| PFE | PFIZER INC | 7.12 | 137.28B | ||
| SNY | SANOFI-ADR | 10.56 | 115.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.73 | 92.17B | ||
| GSK | GSK PLC-SPON ADR | 8.92 | 81.97B | ||
| ZTS | ZOETIS INC | 23.59 | 65.02B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.93 | 47.56B |
Related stock screener links
About HRMY
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: John C. Jacobs
Employees: 268
Phone: 14845399800
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
What is the stock price of HARMONY BIOSCIENCES HOLDINGS today?
The current stock price of HRMY is 32.24 USD. The price decreased by -1.2% in the last trading session.
What is the ticker symbol for HARMONY BIOSCIENCES HOLDINGS stock?
The exchange symbol of HARMONY BIOSCIENCES HOLDINGS is HRMY and it is listed on the Nasdaq exchange.
On which exchange is HRMY stock listed?
HRMY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HARMONY BIOSCIENCES HOLDINGS stock?
17 analysts have analysed HRMY and the average price target is 51.65 USD. This implies a price increase of 60.2% is expected in the next year compared to the current price of 32.24. Check the HARMONY BIOSCIENCES HOLDINGS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HARMONY BIOSCIENCES HOLDINGS worth?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a market capitalization of 1.85B USD. This makes HRMY a Small Cap stock.
How many employees does HARMONY BIOSCIENCES HOLDINGS have?
HARMONY BIOSCIENCES HOLDINGS (HRMY) currently has 268 employees.
What are the support and resistance levels for HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a support level at 31.11 and a resistance level at 37.81. Check the full technical report for a detailed analysis of HRMY support and resistance levels.
Is HARMONY BIOSCIENCES HOLDINGS (HRMY) expected to grow?
The Revenue of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 17.83% in the next year. Check the estimates tab for more information on the HRMY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HRMY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HRMY, evaluating the profitability, health, valuation and growth aspects
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Sales and EPS estimates to see what analysts future expectations are.
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Insider and Institutional Ownership to learn about the owners and their transactions.
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Chart to make your own analysis
- HARMONY BIOSCIENCES HOLDINGS (HRMY) Latest news and press-releases to stay up to date.
Does HARMONY BIOSCIENCES HOLDINGS (HRMY) stock pay dividends?
HRMY does not pay a dividend.
When does HARMONY BIOSCIENCES HOLDINGS (HRMY) report earnings?
HARMONY BIOSCIENCES HOLDINGS (HRMY) will report earnings on 2025-10-27, before the market open.
What is the Price/Earnings (PE) ratio of HARMONY BIOSCIENCES HOLDINGS (HRMY)?
The PE ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.4. This is based on the reported non-GAAP earnings per share of 3.1 and the current share price of 32.24 USD. Check the full fundamental report for a full analysis of the valuation metrics for HRMY.
What is the Short Interest ratio of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?
The outstanding short interest for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 8.55% of its float. Check the ownership tab for more information on the HRMY short interest.
HRMY Technical Analysis
HRMY Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to HRMY. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties.
HRMY Financial Highlights
Over the last trailing twelve months HRMY reported a non-GAAP Earnings per Share(EPS) of 3.1. The EPS increased by 49.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.42% | ||
| ROA | 16.33% | ||
| ROE | 23.4% | ||
| Debt/Equity | 0.2 |
HRMY Forecast & Estimates
17 analysts have analysed HRMY and the average price target is 51.65 USD. This implies a price increase of 60.2% is expected in the next year compared to the current price of 32.24.
For the next year, analysts expect an EPS growth of 27.74% and a revenue growth 17.83% for HRMY